Search

Your search keyword '"Richard Sue"' showing total 13 results
Start Over Author "Richard Sue" Topic medicine.medical_specialty
13 results on '"Richard Sue"'

1. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE)

Author

Gerard J. Criner, Richard Sue, Shawn Wright, Mark Dransfield, Hiram Rivas-Perez, Tanya Wiese, Frank C. Sciurba, Pallav L. Shah, Momen M. Wahidi, Hugo Goulart de Oliveira, Brian Morrissey, Paulo F. G. Cardoso, Steven Hays, Adnan Majid, Nicholas Pastis, Lisa Kopas, Mark Vollenweider, P. Michael McFadden, Michael Machuzak, David W. Hsia, Arthur Sung, Nabil Jarad, Malgorzata Kornaszewska, Stephen Hazelrigg, Ganesh Krishna, Brian Armstrong, Narinder S. Shargill, Dirk-Jan Slebos, Francis Cordova, Parag Desai, Nathaniel Marchetti, Victor Kim, Kartik Shenoy, John Travaline, Jiji Thomas, Lii-Yoong H. Criner, Aaron Thornburg, Terry Thomas, Surya Bhatt, James Michael Wells, Necole Seabron-Harris, Umair Gauhar, Crissie Despirito, Frank Sciurba, Jessica Bon Field, Divay Chandra, Joseph Leader, Roy Semaan, Christina Ledezma, Pallav Shah, Samuel Kemp, Justin Garner, Arafa Aboelhassan, Karthi Srikanthan, Eric Tenda, Anita Abraham, Cai Sim, Momen Wahidi, Kamran Mahmood, Scott Shofer, Kathleen Coles, Guilherme Augusto Oliveira, Betina Machado, Igor Benedetto, Fabio Svartman, Amarilio de Macedo Neto, Leonardo Schreiner, Taiane Vieira, Ken Yoneda, Tina Tham, Daniel Tompkins, Paulo F. Guerreiro Cardoso, Rodrigo Athanazio, Felipe Nominando, Samia Rached, Luciana Cassimiro, Eric Seeley, Pavan Shrestha, Gabriela R. Dincheva, Daniel Alape-Moya, Mihir Parikh, Alichia Paton, Alexis Agnew, Charlie Strange, Tatsiana Beiko, Danielle Woodford, Mary Blanton, Timothy Connolly, Jose Fernando Santacruz, Bhavin Shah, Luis Herrera, Rumi Khan, Kristine Sernulka, Richard Barbers, Michelle Hernandez, Francisco Almeida, Joseph Cicenia, Thomas Gildea, Atul Mehta, Sonali Sethi, Yvonne Meli, David Hsia, Richard Casaburi, William Stringer, Leticia Diaz, Meghan Ramsey, Ryan Van Wert, Karen Morris, Tim Batchelor, Iara Sequeiros, Katy Tucker, Malgorzata Kornaszweska, Hazem Fallouh, Ramsey Sabit, Hatam Naase, Joseph George, Azin Salimian, Helen Dyer, Kristal Adams, Karen Bade, Bryan S. Benn, Michelle Canfield, Sharmila Vetri Villalan, Travis Stewart, Nick H. T. ten Hacken, Karin Klooster, Jorine Hartman, Sonja Augustijn, and Groningen Research Institute for Asthma and COPD (GRIAC)

Subjects
Male, Pulmonary and Respiratory Medicine, CLINICAL-OUTCOMES, medicine.medical_specialty, Randomization, SURGERY, lung reduction, Bronchi, Critical Care and Intensive Care Medicine, OBSTRUCTIVE PULMONARY-DISEASE, chronic obstructive pulmonary disease, MEDICAL THERAPY, Collateral ventilation, law.invention, 03 medical and health sciences, 0302 clinical medicine, Primary outcome, Randomized controlled trial, law, Forced Expiratory Volume, Surveys and Questionnaires, Internal medicine, Bronchoscopy, Correspondence, Humans, COPD, Medicine, 030212 general & internal medicine, LUNG-VOLUME-REDUCTION, Respiratory system, Exercise Tolerance, IMPORTANT DIFFERENCE, business.industry, Walk distance, OPERATIVE MORTALITY, Endobronchial valve, Equipment Design, Prostheses and Implants, Middle Aged, NATIONAL EMPHYSEMA, medicine.disease, Treatment Outcome, emphysema, Pulmonary Emphysema, 030228 respiratory system, TESTS, Female, business
Abstract

Rationale: This is the first multicenter randomized controlled trial to evaluate the effectiveness and safety of Zephyr Endobronchial Valve (EBV) in patients with little to no collateral ventilation out to 12 months.Objectives: To evaluate the effectiveness and safety of Zephyr EBV in heterogeneous emphysema with little to no collateral ventilation in the treated lobe.Methods: Subjects were enrolled with a 2:1 randomization (EBV/standard of care [SoC]) at 24 sites. Primary outcome at 12 months was the Delta EBV-SoC of subjects with a post-bronchodilator FEV1 improvement from baseline of greater than or equal to 15%. Secondary endpoints included absolute changes in post-bronchodilator FEV1, 6-minute-walk distance, and St. George's Respiratory Questionnaire scores.Measurements and Main Results: A total of 190 subjects (128 EBV and 62 SoC) were randomized. At 12 months, 47.7% EBV and 16.8% SoC subjects had a Delta FEV1 greater than or equal to 15% (P Conclusions: Zephyr EBV provides clinically meaningful benefits in lung function, exercise tolerance, dyspnea, and quality of life out to at least 12 months, with an acceptable safety profile in patients with little or no collateral ventilation in the target lobe.

Published
2018

2. Improvements in Clinical Outcomes Associated with Reduction in Hyperinflation with Zephyr Valves

Author

Gerard J. Criner, Nicholas J. Pastis, Frank C. Sciurba, Sri Radhakrishnan, Narinder S. Shargill, Momen M. Wahidi, Hugo Goulart de Oliveira, Pallav L. Shah, Paulo Francisco Guerreiro Cardoso, Hiram Rivas-Perez, Brian M. Morrissey, Dirk-Jan Slebos, Richard Sue, Mark T. Dransfield, and Groningen Research Institute for Asthma and COPD (GRIAC)

Subjects
medicine.medical_specialty, business.industry, Internal medicine, medicine.medical_treatment, Cardiology, medicine, Hyperinflation, business, Reduction (orthopedic surgery)
Published
2019

3. Clinically Meaningful Reduction in Hyperinflation with Zephyr Endobronchial Valves (Zephyr Valve) Associated with Sustained Longitudinal Improvements in Lung Function, Exercise Tolerance, QoL and Dyspnea

Author

Jessica Bon, Surya P. Bhatt, P.F.G. Cardoso, C Strange, H.G. Oliveira, Nathaniel Marchetti, F.C. Sciurba, Umair Gauhar, A. Macedo, Nick H. T. ten Hacken, F.N.D. Oliveira, Justin L. Garner, Shawn Wright, Mark T. Dransfield, Sri Radhakrishnan, G.J. Criner, Nicholas J. Pastis, S. Kemp, Hiram Rivas-Perez, Dirk-Jan Slebos, Richard Sue, Tanya Wiese, Narinder S. Shargill, Momen M. Wahidi, K.Y. Yoneda, and Brian M. Morrissey

Subjects
medicine.medical_specialty, business.industry, Internal medicine, medicine.medical_treatment, medicine, Cardiology, Hyperinflation, business, Reduction (orthopedic surgery), Lung function
Published
2019

4. Reply to Fitzmaurice et al.: The LIBERATE Trial: Options to Reduce the Risk of Post-procedural Pneumothorax and Length of Stay Reply

Author

Dirk-Jan Slebos, Frank C. Sciurba, Gerard J. Criner, Richard Sue, and Groningen Research Institute for Asthma and COPD (GRIAC)

Subjects
Pulmonary and Respiratory Medicine, 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, 030228 respiratory system, Pneumothorax, business.industry, General surgery, Medicine, 030204 cardiovascular system & hematology, Critical Care and Intensive Care Medicine, business, medicine.disease
Published
2018

5. Twelve-month positive outcomes of Zephyr endobronchial valves in severe emphysema patients

Author

Shawn Wright, Hugo De Oliviera, Malgorzata Kornaszewska, Adnan Majid, Arthur Sung, Mark Vollenweider, Paulo Francisco Guerreiro Cardoso, Dirk-Jan Slebos, Lisa Kopas, Nick H. T. ten Hacken, Richard Sue, Hiram Rivas-Perez, Michael Machuzak, Ganesh Krishna, Nicholas J. Pastis, Pallav L. Shah, Steven R. Hays, Frank C. Sciurba, Stephen R. Hazelrigg, Nabil Jarad, Paul Michael McFadden, David W. Hsia, Gerard J. Criner, Mark T. Dransfield, Narinder S. Shargill, Momen M. Wahidi, Brian M. Morrissey, Tanya Wiese, Groningen Research Institute for Asthma and COPD (GRIAC), and Lifestyle Medicine (LM)

Subjects
COPD, medicine.medical_specialty, business.industry, Endobronchial valve, Hyperinflation, medicine.disease, Gastroenterology, respiratory tract diseases, Collateral ventilation, Pneumothorax, Quality of life, Internal medicine, medicine, Volume reduction, Adverse effect, business
Abstract

Introduction: Zephyr® Endobronchial Valve (EBV®) treatment in severe emphysema patients, improves lung function, exercise capacity and quality of life. Objective: Evaluate effectiveness and safety of EBV treatment in severe emphysema. Methods: 190 severe heterogeneous emphysema subjects (M47%/F53%) with hyperinflation (FEV1 27.4 %pred; RV 224.5 %pred) and absent collateral ventilation (Chartis®) were randomized 2:1 (EBV:Standard-of-Care (SoC). Responders were classified according to established Minimal Clinically Important Differences for outcome measures. Results: At 12-months 84.2% EBV subjects had a target lobe volume reduction ≥350mL. Between group differences (ΔEBV–SoC) for mean changes from baseline were significant (p

Published
2018

6. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM)

Author

Paulo Francisco Guerreiro Cardoso, Nabil Jarad, Nicholas J. Pastis, Brian M. Morrissey, Frank C. Sciurba, Hugo Goulart de Oliveira, Lisa Kopas, Gerard J. Criner, Brian Armstrong, Malgorzata Kornaszewska, Michael Machuzak, Hiram Rivas-Perez, Shawn Wright, Mark Vollenweider, Pallav L. Shah, Narinder S. Shargill, Momen M. Wahidi, David W. Hsia, Stephen R. Hazelrigg, Tanya Wiese, Steven R. Hays, Ganesh Krishna, Mark T. Dransfield, P. Michael McFadden, Adnan Majid, Dirk-Jan Slebos, Richard Sue, Arthur Sung, Groningen Research Institute for Asthma and COPD (GRIAC), Lifestyle Medicine (LM), University Medical Center Groningen [Groningen] (UMCG), Service de pneumologie B, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Laboratory of Fundamental and Applied Bioenergetics = Laboratoire de bioénergétique fondamentale et appliquée (LBFA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Centre Hospitalier Universitaire [Grenoble] (CHU), Université de Lorraine (UL), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Lithosphère, structure et dynamique (LSD), Institut des Sciences de la Terre de Paris (iSTeP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Pneumologie et Réanimation Médicale [CHU Pitié-Salpêtrière] (Département ' R3S '), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
Male, SURGERY, [SDV]Life Sciences [q-bio], BELIEVER-HIFI, Medizin, Critical Care and Intensive Care Medicine, THERAPY, law.invention, 0302 clinical medicine, Randomized controlled trial, law, lung volume reduction, collateral ventilation, Forced Expiratory Volume, Surveys and Questionnaires, Medicine, 030212 general & internal medicine, Prospective Studies, LUNG-VOLUME-REDUCTION, Exercise Tolerance, Operative mortality, Prostheses and Implants, Middle Aged, 3. Good health, Treatment Outcome, Pulmonary Emphysema, Female, Pulmonary and Respiratory Medicine, Lung volume reduction, medicine.medical_specialty, CLINICAL-OUTCOMES, Pulmonary emphysema, Pulmonary disease, OBSTRUCTIVE PULMONARY-DISEASE, Collateral ventilation, chronic obstructive pulmonary disease, 03 medical and health sciences, MINIMAL IMPORTANT DIFFERENCE, COPD, Humans, In patient, business.industry, endobronchial valves, Endobronchial valve, Surgery, hyperinflation, INTERLOBAR COLLATERAL VENTILATION, 030228 respiratory system, Quality of Life, business, FOLLOW-UP
Abstract

Rationale: Single-center randomized controlled trials of the Zephyr endobronchial valve (EBV) treatment have demonstrated benefit in severe heterogeneous emphysema. This is the first multicenter study evaluating this treatment approach.Objectives: To evaluate the efficacy and safety of Zephyr EBVs in patients with heterogeneous emphysema and absence of collateral ventilation.Methods: This was a prospective, multicenter 2:1 randomized controlled trial of EBVs plus standard of care or standard of care alone (SoC). Primary outcome at 3 months post-procedure was the percentage of subjects with FEV1 improvement from baseline of 12% or greater. Changes in FEV1, residual volume, 6-minute-walk distance, St. George's Respiratory Questionnaire score, and modified Medical Research Council score were assessed at 3 and 6 months, and target lobe volume reduction on chest computed tomography at 3 months.Measurements and Main Results: Ninety seven subjects were randomized toEBV(n = 65) or SoC(n = 32). At 3 months, 55.4% of EBV and 6.5% of SoC subjects had an FEV1 improvement of 12% or more (P Conclusions: EBV treatment in hyperinflated patients with heterogeneous emphysema without collateral ventilation resulted in clinically meaningful benefits in lung function, dyspnea, exercise tolerance, and quality of life, with an acceptable safety profile.

Published
2017

8. A 52-year-old man with palpitations and a solitary pulmonary nodule

Author

Richard Sue and Arooj S. Kayani

Subjects
Pulmonary and Respiratory Medicine, Male, medicine.medical_specialty, Orthopnea, Critical Care and Intensive Care Medicine, Chest pain, Coronary artery disease, Varicose Veins, medicine, Palpitations, Humans, Family history, Watchful Waiting, Lung, Solitary pulmonary nodule, Pulmonary Coin Lesion, business.industry, General surgery, Angiography, Solitary Pulmonary Nodule, Arrhythmias, Cardiac, Middle Aged, medicine.disease, Surgery, medicine.symptom, Cardiology and Cardiovascular Medicine, business, Tomography, X-Ray Computed, Paroxysmal Nocturnal Dyspnea
Abstract

A 52-year-old white man presented to a pulmonary clinic for evaluation of a 2.3 × 1.7 cm lung nodule. The patient had originally presented to his cardiologist for palpitations. The palpitations were described as a "fluttering" sensation, occurring daily, more often at rest, but not associated with syncope. At the time, he denied dyspnea, paroxysmal nocturnal dyspnea, or orthopnea. The patient had a coronary artery calcium scoring test done, which revealed a lobulated, well-circumscribed, smoothly marginated lower lobe nodule, and he was sent to a pulmonary clinic for further evaluation. The patient denied shortness of breath, chest pain, cough, wheezing, or hemoptysis. He denied fatigue, night sweats, or weight loss. He had a 1 pack-year smoking history and stopped cigarettes 30 years ago but still smoked two to three cigars monthly. His family history was only significant for early coronary artery disease. He was an avid marathon runner who worked as an athletic equipment manager for a prominent sports team in Arizona.

Published
2015

9. Safety of Percutaneous Endoscopic Gastrostomy Tube Placements by Interventional Pulmonologists

Author

Taaran Cariappa Ballachanda Subbaiah, Kurt Olson, Richard Sue, and Rajeev Saggar

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, business.industry, Gastrostomy tube, Percutaneous endoscopic gastrostomy, medicine.medical_treatment, medicine, Tube (fluid conveyance), Cardiology and Cardiovascular Medicine, Critical Care and Intensive Care Medicine, business, Pulmonologists, Surgery
Published
2016

10. The Milky Path to the Diagnosis of an Anterior Mediastinal Mass

Author

Taaran Cariappa Ballachanda Subbaiah, Lee J. McGhan, Jasmine Huang, Tanmay S. Panchabhai, Richard Sue, and Manraj Khosla

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, business.industry, Path (graph theory), medicine, Mediastinal mass, Radiology, Cardiology and Cardiovascular Medicine, Critical Care and Intensive Care Medicine, business
Published
2016

11. [Untitled]

Author

Yunhee Im and Richard Sue

Subjects
medicine.medical_specialty, business.industry, Medicine, Radiology, Mediastinal Lymphangioma, Critical Care and Intensive Care Medicine, business
Published
2014

12. Autofluorescence Bronchoscopy to Evaluate Myofibroblastic Tumors

Author

Mohan Ashok Kumar, Richard Sue, and Nithya Menon

Subjects
Pulmonary and Respiratory Medicine, Autofluorescence, Pathology, medicine.medical_specialty, Bronchoscopy, medicine.diagnostic_test, business.industry, Myofibroblastic tumors, medicine, Cardiology and Cardiovascular Medicine, Critical Care and Intensive Care Medicine, business, Autofluorescence bronchoscopy
Published
2012

13. Tako-Tsubo Cardiomyopathy Occurring 12 Days After Aneurysmal Subarachnoid Hemorrhage

Author

Mohan Ashok Kumar, Priya Radhakrishnan, Richard Sue, and Peter Nakaji

Subjects
Pulmonary and Respiratory Medicine, Takotsubo syndrome, medicine.medical_specialty, Subarachnoid hemorrhage, business.industry, Internal medicine, Cardiology, Medicine, Tako-tsubo Cardiomyopathy, Cardiology and Cardiovascular Medicine, Critical Care and Intensive Care Medicine, business, medicine.disease
Published
2012

Catalog

Books, media, physical & digital resources
See catalog results